TARRYTOWN, N.Y., May 10, 2011 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) today announced its results of operations for the quarter ended March 31.
“The most significant event of our first quarter was completing a license agreement for RELISTOR® with Salix Pharmaceuticals,” said Mark R. Baker, Progenics’ chief executive officer. “I believe Salix’s robust sales and marketing capabilities, and their particular expertise in gastroenterology, are an ideal combination of expertise to drive RELISTOR’s development and commercialization at this important juncture.”
